Objective: Treatment of acute lymphoblastic leukemia (ALL) in adults focuses on the initial assessment of the prognostic relevant cytogenetic features as well as a response-guided therapy based on molecular data. We examined the importance of molecular-cytogenetic abnormalities for complete remission (CR) rates and the overall survival (OS) in adult ALLs. Materials and Methods: Conventional cytogenetics and fluorescence in situ hybridization were performed on bone marrow cells from 33 newly-diagnosed ALL adults. Two karyotype categories [standard-risk group-normal karyotype, hyperdiplody and other structural aberrations, and high-risk group-t(11q23)/MLL, t(9;22)/bcr-abl, t(1;19), t(8;14), C-MYC and complex karyotype] and the biologically and clinically relevant ALL ploidy subgroups were prospectively defined. Results: Chromosomal abnormalities were found in 52% of the cases with a high rate of poor-risk translocations -t(9;22), t(8q24), t(11q23), t(1;19). The total CR rate was 67% and the median time for achievement 2.33 months. Male sex, an age below 35 years and the absence of high risk translocations might have contributed to the high CR rates. Female patients, hyperdiplody, low white blood cells (WBC), and random cytogenetic aberrations had the longest OS. OS, 3-and 5-years survival periods were significantly shorter for poor-risk than standard risk group (p=.015, p=.001 and p=.005, respectively). Conclusion: This study emphasizes the lack of influence of cytogenetic aberrations on the CR and the time to achieve CR. However, our observations show that these aberrations are an independent prognostic factor in adult ALL -they allow predicting therapy resistance and the OS time after intense treatment. (Turk J Hematol 2011; 28: 176-85) 
Introduction
Acute lymphoblastic leukemia (ALL) is a fairly uncommon disease in adults and is associated with a poor prognosis. The treatment of adult ALL is based on the initial assessment of relevant prognostic molecular-cytogenetic features and responseguided therapy based on molecular data. In more than 50% of adult ALL patients clonal chromosomal abnormalities that deregulate candidate oncogenes or transcription factors by introducing a heterologous promoter or enhancer are observed [1] [2] [3] . Altered cell cycle progression or upregulated tyrosine kinase activity are other important mechanisms in ALL [2] [3] [4] [5] . Most translocations can lead to generation of fusion genes that translate into chimeric oncogenic proteins, providing targets for novel therapeutic agents. The most important prognostic factors in ALL are cytogenetic abnormalities, the time to achieve complete remission (CR), the initial leukocyte count, age, and immunologic subtype [4] [5] [6] [7] [8] . Cytogenetic abnormalities observed in ALL patients are among the most important independent prognostic variables that predict outcome; [5, 6, 9] ploidy and translocations are correlated with prognosis [10, 11] ALL is heterogeneous and can be subtyped based on chromosomal, immunophenotypic, and molecular criteria. The prognostic implications of different ALL subtypes strongly influence the choice of treatment in adults [5, 6, 12] . Many patients with T-cell ALL can be cured with chemotherapy alone. In contrast, patients with early B-lineage ALL and certain chromosomal abnormalities, especially the Philadelphia chromosome, do not have durable responses to chemotherapy and should undergo bone marrow transplantation [13, 14] .
The aim of the present study was to determine the frequency and prognostic significance of molecular-cytogenetic abnormalities, and to ascertain whether or not karyotype is a significant prognostic factor in adult ALL patients, independent of new intensive chemotherapy regimens and initial clinical characteristics.
Material and Methods

Study design Patients
The study included 33 patients (aged >18 years) that were newly diagnosed with ALL at Alexandrovska University Hospital, Hematology Clinic, Sofia, Bulgaria during a 3-year period. Diagnosis of ALL was based on the French-American-British (FAB) classification system's morphological and cytochemical criteria, and on lymphoid immunophenotype. [15] . CR was followed by multidrug consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for 24 months.
Definition of remission state CR was defined as ≤5% blast cells in normocellular or hypercellular bone marrow, a normal peripheral and differential blood count, and no extramedullary disease. Complete remission time was defined as the time from diagnosis to CR.
Definition of resistant disease
ALL was considered as resistant disease (RD) if CR was not achieved after 3 courses of induction therapy.
Definition of overall survival
Overall survival (OS) was the time of treatment onset to the time of death. Patients were censored for survival only at the date they were last known to be in complete remission or alive, respectively.
Methods
Immunophenotyping
Immunophenotyping was performed at Alexandrovska University Hospital, Allergology and Immunology Clinic. Leukemic cells obtained from fresh bone marrow or peripheral blood samples collected in EDTA-containing tubes were analyzed. Surface, cytoplasmic, and nuclear antigens were detected via a standard 2-color direct immunofluorescence assay using a broad panel of commercially available lymphoid and myeloid-associated monoclonal antibodies (MoAbs).
According to the European Group for Immunophenotyping of Leukemia (EGIL) [16] , B-lineage acute leukemias were separated into the following 4 groups: pro-B-ALL (BI): CD19+, CD22+, cyCD79a+, CD10-cyIg-, and sIg-; common B-ALL (BII): CD10+ (CALLA+), cyIg-, sIg-; pre-B-ALL (BIII): CD10+/-, cyIg+, and sIg-; mature B-ALL (BIV): sIg+. T-lineage ALL was characterized based on CD1a, CD2, CD3, CD4, CD5, CD7, and CD8 cell marker expression. Myeloid markers (CD13, CD33, CD14, and CD15) were tested in most patients. For every antigen tested cell expression >20% was considered a positive reaction.
Conventional cytogenetics
Conventional (routine) cytogenetic analysis was performed on material obtained from bone marrow aspiration. Bone marrow was treated with direct (without cell cultivation) and indirect methods (after 48 h of cultivation with 15% fetal bovine serum at 37°C in RPMI) to obtain metaphases. Chromosomes were stained using the G-banding method and were analyzed via light microscopy and Icarus Metasystem software. Karyotypes were determined according to International System for Human Cytogenetic (ISHC) nomenclature [17] . The presence of ≥2 metaphases with the same structural change, the same chromosome gain, or ≥3 metaphases with deletion of the same chromosomes was considered as clonal aberration. At least 20 metaphases for each patient were carried out. Hypodiploid and hyperdiploid karyotypes were defined as having <45 and >46 chromosomes, respectively.
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on cytogenetic preparations obtained from bone marrow cells. Direct labeling locus-specific probes (Vysis, Ltd.) were used for MLL gene rearrangements, bcr/abl gene fusion, and C-MYC rearrangements. Fluorescence signals were detected using fluorescence microscopy and ISIS Metasystem software. The size of genetically abnormal clones was determined after analyzing at least 100 successfully hybridized cells.
Statistical methods
The statistical variables tested for potential prognostic value were as follows: molecular-cytogenetic abnormalities, age, WBC count, hemoglobin value, platelet (PLT) count, immunologic subgroup, CR rates, frequency of RD, early deaths, and survival times. Three-and 5-year survivals were estimated using the life tables' method. Kaplan-Meier [18] curves were constructed for CR time and survival; A Log rank test was used to compare these curves in both cytogenetic groups.
Comparison of quantitative variables between patient groups was performed using one-way analy-
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Turk J Hematol 2011; 28: 176-85 sis of variance. Comparison of qualitative data was performed using the chi-square test and t-test. All statistical analyses were 2-sided. P values <0.05 were considered statistically significant. Cytogenetic abnormalities were classified into 2 groups, as follows: 1) high risk: t(11q23)/MLL, t(9;22)/bcr-abl, hypodiploidy (<45 chromosomes), t(1;19), t(8q24)/C-MYC, and complex karyotype; 2) standard risk: normal karyotype, hyperdiploidy, and other structural aberrations. The parameters were selected according to internationally accepted prognostic factors in ALL [7, 11, [19] [20] [21] . As a prognostic factor, cytogenetics was considered a binomial variable (high-risk group versus standard-risk group).
Results
Clinical and biological characteristics of the patients
Clinical and biological characteristics of the patients are shown in Table 1 . The frequency of ALL increased with age; 61% of the patients were aged >35 years. More patients had B-cell leukemia (84.8%) than T-cell leukemia (15.2%, p<0.001), and most had a WBC count <30.10 9 /L (82%, p<0.001).
Cytogenetic data and correlations with clinical and hematological features
Based on routine cytogenetic and FISH analysis, clonal chromosomal abnormalities were noted in 17 *OS in T-lineage ALL was not estimated because more than 50% of the patients died. Median OS is the time, which are gone through 50% of patients in the respectively group, CR-complete remission; OS-overall survival of the 33 ALL patients (52%). Ploidy groups and structural changes were analyzed ( Table 1) . The ALL patients were divided into 2 risk groups (Table 2) according to molecular-cytogenetic aberrations, and basic biological and laboratory parameters at the time of diagnosis: high risk (n=14, 42.4%) and standard risk (n=24, 69.7%). (Table 1) . Among the pseudodiploid karyotypes, changes were variable. The following chromosomes were involved with high frequency in balanced translocations: 4, 7, 8, 9, 11, 14, and 22. The short arms of chromosomes 4 and 12 were involved in deletion events. In 3 patients hyperdiploidy (>46) was combined with structural aberrations t(9;22), del 12p, and del l4p. The incidence of hyperdiploid cell lines in individual patients ranged between 20% and 100% of the analyzed metaphases; chromosomes 8, 6, 12, and 21 were the most frequently involved.
Cell ploidy abnormalities
Structural abnormalities
Structural changes were observed in 17 patients (52%) with high-risk translocations t(9;22)(q34;q11), t(8q24), t(11q23), and t(1;19)(q23;p13). The other structural abnormalities exhibited deletion of the short arm of chromosomes 4 and 12, and isochromosome 7.
Differences in CR rates
The CR rate for the 33 patients was 67%; 11 patients did not achieve CR. The median time to achieve CR was 2.33 months (range: 1.47-3.19 months). Male gender, T-marker expression, age <35 years, and absence of high-risk translocations (Table 4 ), but the number of patients with these aberrations was very low-5 of 33 cases. Female gender, age >35 years, Burkitt's-type ALL, and pseudodiploidy were associated with the shortest time to first CR ( Table 1 ). The median time to achieve CR was not statistically different between the 2 groups 2.3 months in the standard-risk group and 1.9 months in the high-risk group (p=0.515) ( Table 3 ). Patients with t(9;22)/bcr-abl had the longest time to CR and the highest RD rate (Table 4) .
Differences between 3-year, 5-year, and overall survival
Patients with hyperdiploidy karyotypes, a low WBC count, random cytogenetic aberrations, and females had the longest OS ( Table 1) . As indicated in Table 3 and the Figure, median OS was significantly shorter in the high-risk group (9.85 months) than in the standardrisk group (18 months) (p=0.015). The estimated 3-year survival was 19.5% for all patients; 10% for the high-risk group vs. 29% for the standard risk group (p=0.001). In all, 17% of the patients had 5-year survival; 10% in the high-risk group and 24% in the standard risk group (p=0.005). A significant difference in OS was observed between the patients with and without CR (p=0.001) ( Table 5) .
A comparison of the frequency and types of molecular-cytogenetic aberrations in the immunological subgroups is presented in Table 6 . The frequency of В-lineage ALL (28 cases, 84.8%) was statistically higher than T-lineage ALL (5 cases, 15.2%) (p<0.001). Among the B-ALL patients, 60.7% were common B-ALL (BII), 17.9% were pro-B ALL (BI), 17.9% were mature B-ALL (B-IV), and 3.5% were pre-B ALL (B-III).
Discussion
It has been reported that cytogenetics is the most important prognostic factor in adult ALL patients [12, [22] [23] [24] [25] . Based on their results, these researchers were able to classify patients into standard-, intermediate-, and high-risk groups with significant differences in survival.
The present study compared patient characteristics, molecular-cytogenetic data, CR, and OS in a group of 33 newly diagnosed adult ALL patients that were treated with the standard adult ALL protocol. In all, 42.4% of the patients were included in the high-risk group. All the patients were aged >35 years (except MLL (+) patients with a median age of 25 years, p=0.02). The median time to achieve CR differed insignificantly between the 2 molecularcytogenetic groups. Interestingly, time to CR was shorter in the high-risk group than in the standardrisk group.
The Philadelphia (Ph) chromosome was the most frequent karyotypic aberration in the high-risk group (35.7% in the high-risk group versus 15.15% in all 33 ALL patients), which is higher than previously reported (15%-30%) [7, 13, 19, [26] [27] [28] [29] [30] . Our observa- CR-complete remission; RD-resistant disease tion pointed for variable immunophenotypes in Ph(+) ALL, without any apparent connection to a specific phenotype. Leukemic blasts in Ph(+) ALL expressed B-lineage-specific markers and aberrant myeloid markers in 3 of the 4 cases. According to Tabernero et al., [31] the frequency of myeloid coexpression in Ph(+) ALL is higher than that in Ph(-) ALL. High myeloid expression of CD13, CD33, and CD15 in 75% of lymphoblasts in Ph(-) ALL has been observed. In the present study patients with t(9;22) and/or bcr/abl rearrangements had a 60% CR rate and longer time to CR (2.73 months) than other cases in the high-risk group.
In all, 14.3% of the high-risk patients and 6.1% of all the patients in the present study had t(4; 11) (q21;q23) translocation and/or rearrangement of the MLL gene. Most leukemic blasts with this translocation had a pro-B-ALL or CALLA(+) phenotype. One MLL(+) patient expressed myeloid antigens CD33 and cyCD13 without fulfilling the criteria for biphenotypic leukemia. The lowest median age was in patients with 11q23/MLL and a high correlation index (r=0.999) of the translocation with a high leukocyte level (median WBC count: 95.5×10 9 /L). CR was achieved in 1 of the MLL cases. The time to CR was the shortest (1 month), despite the presence of markers of poor prognosis (high WBC count and myeloid co-expression). These findings highlight the difficulty in confirming the independent prognostic importance of relatively small cytogenetic subgroups that are strongly correlated with other risk factors, such as the WBC count and age [20, 23, [32] [33] [34] . In the present study the frequency of 8q24 translocations and/or rearrangements of the C-MYC proto-oncogene was high 28.6% in the highrisk group and 12% in all 33 patients. Translocations (8q24)/C-MYC are the molecular-cytogenetic label of Burkitt's leukemia/lymphoma [7, 21, 22, 34, 35] . Interestingly, only 3 of the 33 patients in the present study had typical mature B-cell phenotype-positive CD19, CD20, CD10, surface IgM, and CD 79a, and negative CD5, CD23, and TdT. Among the pre-B-ALL patients, involvement of the MYC gene was confirmed in 1. This is not the first time that t(8;14) has been reported beyond the context of mature B-ALL [36] . The presence of t(8q24)/C-MYC is associated with poor prognosis and a low CR rate [7, 23, 33, 35, 37] . We observed a high CR rate (75%) in the present study, but 50% of 8q24 cases had RD or early death in the 3 months following diagnosis.
Translocation t(1;19)(q23;p13) was observed in 1 (2.9%) of the ALL patients in the present study; the patient had a high WBC count (69.6×10 9 /L), very low hemoglobin (49g/L), and low PLT count (10x10 9 /L). This translocation is a rare cytogenetic aberration in adult ALL and correlates with immature B-lineage phenotypes, especially pro-B-ALL [7, 32, 37, 38] . The patient's leukemic blasts presented as non-typical for t(1;19) more mature immunophenotype with expression of CD10 (CALLA ) antigens. CR in this t(1;19)(+) patient was achieved rapidly and without therapy resistance 1 month after starting the initial treatment.
Complex chromosomal abnormalities are rare in To date, analysis of cytogenetic aberration changes in cell ploidy in adult ALL patients are rare, but are most often combined with structural abnormalities (pseudodiploid (46, abnormal) . Most likely they have no clear self-diagnostic or prognostic significance, as in pediatric ALL patients [10, 11, 35, 40] . Poor prognosis associated with pseudodiploidy is likely a reflection of structural rearrangements and other unfavorable features. CR was achieved in patients with the hyperdiploidy karyotype only among those without t(9;22) or bcr/abl rearrangements.
Among the structural aberrations in adult ALL, deletions and isochromosomes were the second most frequent changes after translocations [7, 11, 33] . These chromosome abnormalities are usually classified as miscellaneous or random changes with an unclear disease prognosis [12, 22, 23] Inactivation of tumor suppressor genes located in regions 4p, 12p, and 7q often leads to the start of a leukemic process [7, 11, 33, 41] . In all but 1 of the patients in the present study with a combination of del(4p) and t(4;11) deletions presented as single cytogenetic aberrations. Despite having unfavorable pretreatment laboratory characteristics (age >35 years and low PLT count), the patients with miscellaneous abnormalities had a better CR rate than the patients with nonrandom chromosome changes.
Distribution of immunophenotypes in the present study was similar to that previously published [41] [42] [43] . Numerical and structural translocations were more frequent in the mature B-ALL (75% of B IV cases) and pre-B-ALL (100%) patients. A lot of them were with poor prognostic significancet(9;22)/bcr-abl, t(8q14)/C-MYC and complex karyotype. The high CR rate in these patients (100% in pre-B-ALL and 75% in mature B-ALL) show that molecular-cytogenetic abnormalities were important, but not determinative of the achievement of the first CR, and that pretreatment laboratory and biological characteristics affected the management of the disease. The most common lymphoblast leukemia among the presented patients was common B-ALL (51.5%), which was associated with a high WBC count at presentation and high-risk cytogenetic aberrations. The common B-ALL patients had a higher incidence of Ph/bcr-abl(+) leukemia (24% of the common B-ALL cases) and a lower CR rate (64.7%) than the mature B-ALL patients. The pro-B-ALL (BI) patients had the lowest CR rate (40%), despite the presence of standard-risk cytogenetic changes. It is likely that the immunologically immature features of leukemic blasts were associated with poor disease outcome. In all, 25%-30% of adult ALL cases have T-lineage ALL [42, [44] [45] [46] . We studied a small group of T-ALL patients (15.2% of all ALL cases) and observed a higher CR rate in the T-ALL patients than in the B-ALL and Burkitt's-type leukemia patients. The CR rate in the adult ALL patients appeared to be influenced positively by the absence of high-risk translocations and favorable pretreatment laboratory characteristics.
Conclusion
The present study shows that karyotype was an independent prognostic factor in the adult ALL patients for predicting OS following intensive treatment regimens, and that laboratory and biologic features (age, and WBC and PLT counts), and immunophenotype greatly influenced CR and disease outcome.
This small cohort of adult ALL cases and the high-quality cytogenetic data obtained demonstrate the value of cytogenetics for identifying patients with high and low risk of treatment failure. Future randomized clinical trials on adult ALL can and should use cytogenetic data to stratify patients into appropriate risk groups, so as to ensure they receive the most suitable therapy.
Additional cytogenetic and molecular genetic Turk J Hematol 2011; 28: 176-85 studies of adult ALL are urgently required to further characterize this disease, thereby increasing the number of patients than can benefit from alternative treatment strategies.
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